论文部分内容阅读
目的探讨胃癌5p15.33区微卫星标记杂合性缺失(LOH)与临床病理学表型的相关性。方法抽提80例胃癌标本及其配对正常胃黏膜中基因组DNA,应用4个微卫星标记对5p15.33区进行LOH检测并与Lauren分型等临床病理学指标分析。结果有76例临床信息齐全病例纳入统计分析。5p15.33区4个微卫星标记平均信息性病例比例为71.05%。其中31.58%(24/76)病例至少一个位点检测到LOH,以D5S2849位点LOH频率最高(37.25%)。5p15.33位点LOH以肠型胃癌多见(P<0.01),与年龄、性别、部位、肿瘤大小、TNM分期及有无淋巴结转移无明显关系。结论5p15.33区可能存在控制胃癌形态学表型的候选抑癌基因,但该基因可能不是决定其他临床表型的主要基因。
Objective To investigate the relationship between microsatellite-labeled heterozygous deletion (LOH) and clinicopathological phenotype in gastric cancer 5p15.33. Methods Genomic DNA was extracted from 80 gastric cancer specimens and matched normal gastric mucosa. Four microsatellite markers were used to detect LOH in 5p15.33 area and Lauren classification and other clinicopathological parameters. Results A total of 76 cases of clinical information were included in the statistical analysis. In the 5p15.33 region, the average informative cases of 4 microsatellite markers were 71.05%. Among them, LOH was detected in at least one locus in 31.58% (24/76) cases, and the highest LOH frequency was observed in D5S2849 locus (37.25%). LOH at 5p15.33 site was more common in intestinal type gastric cancer (P <0.01), and had no significant relationship with age, sex, location, tumor size, TNM stage and lymph node metastasis. Conclusion There may be a candidate tumor suppressor gene in the 5p15.33 region to control the morphological phenotype of gastric cancer. However, this gene may not be the major determinant of other clinical phenotypes.